Special Issue "Human Parainfluenza"
Deadline for manuscript submissions: 28 February 2022.
Interests: respiratory viruses; host–virus interactions; host–virus co-evolution; glycovirology; antiviral drug design and development; ex vivo tissular models; sialic acid; blood group antigens
First isolated in the late 1950s, human parainfluenza viruses (HPIV) are enveloped single-stranded RNA (-) viruses, members of the family Paramyoviridae. Worldwide, HPIV are important respiratory pathogens responsible for acute lower respiratory infections (LRI) such as croup, bronchiolitis, and pneumonia in young children, the elderly and immunocompromised people, the latest group presenting an increased risk of mortality associated to HPIV infection. Despite important research efforts, no drugs or vaccines are currently approved for treatment or prevention of HPIV LRI. Amongst all HPIV proteins, the surface glycoproteins hemagglutinin–neuraminidase (HN) and fusion (F) have been the main targets for HPIV antiviral drug design and vaccine development. HN is known to bind specifically to terminal sialic acid (Neu5Ac) decorating glycoconjugates at the surface of respiratory epithelial cells, while F contributes to hPIV nucleocapsid entry to target cells. In addition, HN cleaves terminal Neu5Ac from HPIV glycoreceptor(s) to facilitate HPIV progeny release, to prevent virions aggregates and de novo binding to hPIV infected cells. Moreover, HN and F are essential to generate neutralizing antibodies following HPIV infection. Despite the central roles of HN and F in the HPIV lifecycle and adaptative immunity, other HPIV proteins as well as host-specific proteins and functions may represent interesting targets for the development of novel therapeutics and vaccine candidates.
This Special Issue of Viruses seeks to cover all aspects of current knowledge on human parainfluenza viruses, including, but not restricted to, epidemiology, virus evolution, host–virus interactions, viral replication, infection models, immunology and inflammation, therapeutics, and vaccines. It will incorporate original research articles, reviews, and commentaries to illustrate and discuss the current state of the field, recent discoveries, as well as remaining gaps in knowledge.
Dr. Patrice Guillon
Dr. Larissa Dirr
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- virus–host interactions
- molecular interaction
- viral replication
- antiviral drug design
- vaccine development
- inflammation and immune response